Filing Analysis
Whitehawk Therapeutics reported the voting results from its annual meeting of stockholders held on June 11, 2026. The meeting covered the election of Class III directors, advisory approval of executive compensation, and the ratification of BDO USA, P.C. as the independent auditor.
📋 Key Facts
- Annual meeting held on June 11, 2026, with 40,375,023 shares present (approx. 82% of voting power).
- Three Class III directors (Behzad Aghazadeh, Ph.D., Richard Maroun, and Emma Reeve) were elected.
- Executive compensation for named officers was approved on an advisory basis (22,896,061 For vs 6,013,600 Against).
- BDO USA, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Whitehawk Therapeutics, Inc. announced an option agreement with Hangzhou DAC Biotechnology to expand its antibody drug conjugate (ADC) pipeline. The agreement provides Whitehawk with access to the linker-payload CPT113 for up to five additional ADC programs.
📋 Key Facts
- Whitehawk Therapeutics entered into an option agreement with Hangzhou DAC Biotechnology on or before May 21, 2026.
- The agreement grants access to the linker-payload CPT113 for use in up to five additional ADC programs.
- Hangzhou DAC is presenting data for DXC006, which utilizes the CPT113 linker-payload, at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Whitehawk Therapeutics announced a $87.5 million PIPE financing through the sale of common stock and pre-funded warrants. The transaction includes significant participation from company insiders and affiliated funds, who committed approximately $39.75 million of the total capital.
🚩 Red Flags
- Significant related-party transaction with insiders and affiliated funds contributing 45% of the total financing.
- Substantial potential dilution from the issuance of over 17.9 million pre-funded warrants.
📋 Key Facts
- Total PIPE financing of $87.5 million consisting of 4,330,866 shares of common stock and 17,991,021 pre-funded warrants.
- Common stock priced at $3.92 per share; pre-funded warrants priced at $3.9199 with a $0.0001 exercise price.
- Insiders, including executive officers and affiliated funds of directors, committed $39,750,000 to the offering.
- The company must file a resale registration statement within 30 days of closing and seek effectiveness within 60-90 days.
- Executive officers and directors are subject to a 60-day lock-up period following the closing.
- Placement agents include Jefferies LLC, Leerink Partners LLC, and Oppenheimer & Co. Inc.
Whitehawk Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release and filed under Item 2.02 of Form 8-K.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026
- Press release issued on May 7, 2026
- Filing signed by Chief Financial Officer Scott Giacobello
- Information is furnished under Item 2.02 and not deemed 'filed' for Section 18 liability
Whitehawk Therapeutics, Inc. (WHWK) filed an 8-K on March 12, 2026, announcing its financial results for the fiscal year ended December 31, 2025. The results were disclosed via a press release attached as Exhibit 99.1. This filing is a standard disclosure under Item 2.02.
📋 Key Facts
- Company reported results for the fiscal year ended December 31, 2025.
- The report was filed on March 12, 2026.
- The filing was signed by Scott Giacobello, Chief Financial Officer.